SCHEMBL4675935

SCHEMBL4675935

O=C(O)C(O)=CC(=O)c1cc(S(=O)(=O)c2ccccc2)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 4/20 0.46
NAMPT P43490 3/20 0.37
HTR6 P50406 1/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
RAC1 P63000 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677419 0.88 AKR1B1 (0.47) AKR1B1NAMPTHTR6ALDH1A1MAPT
SCHEMBL4674703 0.88 AKR1B1 (0.47) AKR1B1NAMPTHTR6SMN1; SMN2ALDH1A1
SCHEMBL4672654 0.75 HTR6 (0.40) NAMPTHTR6SMN1; SMN2ALDH1A1GAA
SCHEMBL4672652 0.75 HTR6 (0.40) NAMPTHTR6SMN1; SMN2ALDH1A1GAA
SCHEMBL4678628 0.73 HTR6 (0.37) HTR6SMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL4678633 0.73 HTR6 (0.37) HTR6SMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL4677585 0.71 NOTUM (0.35) TP53ALDH1A1GAAMAPT
SCHEMBL4675551 0.71 HCAR2 (0.41) TP53
SCHEMBL4674415 0.71 HTR6 (0.38) AKR1B1NAMPTHTR6ALDH1A1GAA
SCHEMBL4673980 0.70 NPSR1 (0.38) HTR6SMN1; SMN2ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1B1 17/4885NAMPT 2333/4885HTR6 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.